(LIXT)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Lixte Biotechnology Holdings, Inc., klinik biomavhida kompaniya, saraton dori-darmonlarini ishlab chiqish uchun maqsadlarni aniqlashga, shuningdek, saratonni davolashni ishlab chiqish va tijoratlashtirishga qaratilgan. Uning yetakchi dori nomzodi, LB-100, mikrosatellit barqaror metastatik kolorektal saraton kasalligi bo'lgan bemorlar uchun Atezolizumab bilan birgalikda 1b-bosqichli klinik sinovlarda. Kompaniyaning LB-100 dori vositasi doxorubitsin bilan birgalikda ilg'or yumshoq to'qima sarkomasi uchun 1b-bosqichda; va LB-100 dostarlimab bilan birgalikda tuxumdonning yorug' hujayrali karsinomasini davolash uchun 1b/2-bosqichda. Kompaniya Niderlandiya Saraton Instituti bilan klinik tadqiqotlar bo'yicha tadqiqot shartnomasiga ega; Ispaniya Sarkoma Guruxi bilan tadqiqotchi tomonidan boshlangan klinik tadqiqotlar bo'yicha hamkorlik shartnomasi; va Niderlandiya Saraton Instituti bilan hamkorlikni rivojlantirish bo'yicha kelishuv. Lixte Biotechnology Holdings, Inc. 2005 yilda tashkil etilgan va Pasadena, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Bastiaan van der Baan M.Sc. | Chief Scientific Officer |
| Mr. Geordan G. Pursglove | CEO, President & Chairman |
| Mr. Peter M. Stazzone | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-20 | 8-K | form8-k.htm |
| 2026-03-10 | 8-K | form8-k.htm |
| 2025-12-31 | 8-K | form8-k.htm |
| 2025-12-23 | 8-K | form8-k.htm |
| 2025-12-22 | 8-K | form8-k.htm |
| 2025-12-11 | 8-K | form8-k.htm |
| 2025-11-25 | 8-K | form8-k.htm |
| 2025-11-12 | 10-Q | form10-q.htm |
| 2025-10-28 | DEFA14A | formdefa14a.htm |
| 2025-10-27 | DEF 14A | formdef14a.htm |